



**CCS/CCTN Position Statement on Heart Transplant Patient Eligibility, Selection, and Post-Transplant Care**

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca).

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit
<b>Primary Panel</b>			
Brian Clarke	Abbott, Novartis, Servier (no relationship to statement)	Abbott Canada, Astra Zeneca, Bayer, Boehringer Ingelheim, Merck, Otsuka, St. Jude Medical (no relationship to statement)	None
Sharon Chih	Abbott Canada, Abiomed (no relationship to statement)	Merck, Novartis	None
Susan E. Abbey	None	None	None
Kim Anderson	Novartis, Sanofi (no relationship to statement)	Amgen, Bayer, Boehringer Ingelheim, Merck (no relationship to statement)	None
Mitesh V. Badiwala	None	None	None
Christine Bourgault	Abbott Canada	None	None
Patricia Campbell	None	None	None
Ryan Davey	Abbott Canada, Medtronic, Novartis, Servier, Actelion (no relationship to statement)	AstraZeneca, Bayer, Daiichi-Sankyo, Actelion (no relationship to statement)	None
Anne I. Dipchand	None	None	None
Anique Ducharme	Amgen, Novartis, Servier (no relationship to statement)	Abbott Canada, Abbott Vascular, Novartis, Servier	None
Annemarie Kaan	Servier (no relationship to statement)	None	None
Daniel Kim	None	None	None
Michael McDonald	AstraZeneca, Novartis, Servier (no relationship to statement)	Novartis (no relationship to statement)	None
Lisa Mielniczuk	Bayer, Novartis, Servier (no relationship to statement)	Amgen, AstraZeneca, Bayer, Novartis (no relationship to statement)	None
Mustafa Toma	AstraZeneca, Novartis, Servier (no relationship to statement)	Boehringer Ingelheim, Novartis (no relationship to statement)	None
Shelley Zieroth	Abbott, Akcea, Alnylam, Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Cardiol Therapeutics, Novartis, Servier (no relationship to statement)	Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Merck, Novartis (no relationship to statement)	None
<b>Secondary Panel</b>			
Eric Belanger	None	None	None
Michel Carrier	None	None	None

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.		
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit
Jennifer Conway	None	None	None
Karen Doucette	GlaxoSmithKline, Merck, Gilead (no relationship to statement)	GlaxoSmithKline, Merck, Gilead, Shire (no relationship to statement)	None
Nadia Giannetti	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer Alliance, Novartis, Servier	Amgen, Boehringer Ingelheim, Merck, Novartis, Pfizer, Servier	None
Debra Isaac	None	AstraZeneca, Merck, Novartis, Otsuka (no relationship to statement)	None
Roderick MacArthur	Abbott Canada (no relationship to statement)	None	
Mario Senechal	None	None	None